This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

The telehealth and wellness stock tanked more than 12% Aug. 5, a day after posting mixed Q2 earnings. More importantly, Bank ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

In this strange new world where a weekly injection can quickly achieve what years of attempted diets may fail to do, the ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Influencer Tana Mongeau has warned against taking the weight loss drug Mounjaro after she experienced severe side effects.

Novo Nordisk is facing a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to increased competition and potential US tariffs.

The health and beauty firm behind the Myprotein brand has said its profits will fall by £13m because of the high price of key ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The pharmaceutical giant has witnessed significant revenue boosts from its ...